Non-small Cell Lung Cancer
Conditions
Brief summary
Observe the effect os radiotherapy plus or not plus endostar in the treatment of brain metastasis in NSCLC
Detailed description
The investigators will observe the time controlled by the brain lesion after the test and the total survival time of the patients. Meanwhile, during each follow-up, the investigators will extract cerebrospinal fluid for genomic analysis of cerebrospinal fluid
Interventions
DRUGendostar
endostatin
DRUGPlacebos
saline solution
RADIATIONradiotherapy
radiotherapy
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* NSCLC Brain metastasis
Exclusion criteria
* KPS\<60
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From date of randomization until the date of first documented progression of brain lesions, and the maximum evaluation time is 36 months | the time from the start of treatment to the progression of the brain metastases, in months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival （OS） | From date of randomization until the date of death, assessed up to 36 months | the total survival time of the patient from the start of treatment |
Countries
China
Contacts
Primary Contactdong xiaorong, Dr
Outcome results
None listed